TLR9 and neoplasm: The target tumor cells were added to BMDMs activated by the following TLR agonists; TLR1/2 agonist Pam3, TLR2/6 agonist LTA, TLR3 agonist poly(I:C), TLR5 agonist flagellin, TLR7 agonist CL264, and TLR9 agonist CpG (Figures 2A–F).